Enhertu (trastuzumab deruxtecan), a targeted therapy for HER2-positive cancers, has shown promise in treating solid tumors, including nonsmall cell lung cancer (NSCLC) with brain metastases. This evidence concerns the gene ERBB2 and cancer.